NavneetDhillonMD

Oncology • Canton, GA

Breast Cancer, Hematologic Oncology, Hospice & Palliative, Melanoma

Hematologist/Oncologist at Northside Cancer Institute, Atlanta, GA

Join to view full profile

Dr. Dhillon is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
Connect with colleagues in the same hospital or clinic.
Read the latest clinical news, personalized to your specialty.

See Dr. Dhillon's full profile

Already have an account?

Office
228 Riverstone Dr
Canton, GA 30114
Phone+1 770-479-1870

Fax+1 770-479-9705

Education & Training

University of California (San Francisco)Fellowship, Hematology and Medical Oncology, 2009
University of Texas Health Science Center at Houston/M D Anderson Cancer CenterFellowship, Hematology and Medical Oncology, 2007
U Texas MD Anderson Cancer Ctr2005
University of Texas Medical Branch HospitalsResidency, Internal Medicine, 2004
Government Medical College ChandigrahClass of 1997

Certifications & Licensure

GA State Medical License 2009 - 2025
CA State Medical License 2007 - 2023
TX State Medical License 2005 - 2009
American Board of Internal Medicine Medical Oncology

Clinical Trials

Temozolomide or Selumetinib in Treating Patients With Metastatic Melanoma of the Eye Start of enrollment: 2010 Jun 01
Completed
Phase 2
A Study of Lapatinib in Combination With Everolimus in Patients With Advanced, Triple Negative Breast Cancer Start of enrollment: 2010 Dec 01
Terminated
Phase 2
Dovitinib for Patients With Tumor Pathway Activations Inhibited by Dovitinib Start of enrollment: 2013 Aug 01
Completed
Phase 2
BKM120 for Patients With PI3K-activated Tumors Start of enrollment: 2013 Mar 29
Completed
Phase 2
MEK162 for Patients With RAS/RAF/MEK Activated Tumors Start of enrollment: 2013 Oct 10
Completed
Phase 2
Open-label, Phase II Study of Stomatitis Prevention With a Steroid-based Mouthwash in Post-menopausal Women With Estrogen-receptor-positive (ER+), Human Epidermal Growth Factor Receptor 2 (HER2)- Metastatic or Locally Advanced Breast Cancer Start of enrollment: 2014 May 01
Completed
Phase 2
LEE011 for Patients With CDK4/6 Pathway Activated Tumors (SIGNATURE) Start of enrollment: 2014 Aug 25
Completed
Phase 2
Join now to see all

Publications & Presentations

PubMed

189 citations
Development of a Prognostic Genetic Signature to Predict the Metastatic Risk Associated with Cutaneous Melanoma
Pedram Gerami, Robert W. Cook, Jeffrey Wilkinson, Maria C. Russell, Navneet Dhillon
Clinical Cancer Research. 2015-01-01
25 citations
Drug-induced pulmonary arterial hypertension: a primer for clinicians and scientists.
Mark Orcholski, Ke Yuan, Charlotte M. Rajasingh, Halley Tsai, Elya A. Shamskhou
American Journal of Physiology. Lung Cellular and Molecular Physiology. 2018-06-01
51 citations
Persistent circulation of soluble and extracellular vesicle-linked Spike protein in individuals with postacute sequelae of COVID-19.
Vaughn Craddock, Aatish Mahajan, Leslie Spikes, Balaji Krishnamachary, Anil K Ram
Journal of Medical Virology. 2023-02-01

Professional Memberships

American Society of Clinical Oncology - ASCO
Member

Other Languages

Hindi, Punjabi, Urdu